Gemmer Asset Management’s Sarepta Therapeutics SRPT Stock Holding History

Gemmer Asset Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-3	Closed	–	–	1430
2019 Q3	$0	Buy	+3	New	+$354	﹤0.01%	1463

Other funds holding SRPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Gemmer Asset Management's SRPT Position: Q4 2019 in Review

Gemmer Asset Management sold out of Sarepta Therapeutics (SRPT) in Q4 2019, closing a stake of 3 shares.

Gemmer Asset Management first reported a position in SRPT in Q3 2019 and held it in 1 quarter. The position peaked at $0 in Q3 2019. 389 funds tracked by Wall St. Rank hold SRPT as of Q4 2019.

Gemmer Asset Management reported no remaining Sarepta Therapeutics position as of Q4 2019 after selling out during the quarter.
Gemmer Asset Management sold 3 Sarepta Therapeutics shares in Q4 2019.
Gemmer Asset Management first reported a position in Sarepta Therapeutics in Q3 2019 and held it in 1 quarter.
Gemmer Asset Management's Sarepta Therapeutics position peaked at $0 in Q3 2019.
389 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2019.

Based on Gemmer Asset Management's 13F filing for Q4 2019, filed 17 Jan 2020.